Treatment of COVID-19 patients with Narsoplimab, an inhibitory anti-MASP-2 antibody, had beneficial effect and strongly suggested that endothelial injury-induced activation of MASP-2 and the LP play a central role in the pathophysiology of COVID-19-related lung injury [9,10]. Here, MASP2 is linked to injury.